Patheon — Q3 2007 Earnings Presentation
13 slides from Patheon's earnings presentation, Sep 7, 2007
Slide 1: Q3 2007 Financial Results Conference Call
Q3 2007 FINANCIAL RESULTS CONFERENCE CALL September 7, 2007 10:00 a.m. (EDT) Representing Patheon z RICCARDO TRECROCE Chief Executive Officer z NICK DIPIETRO President and Chief Operating Officer z JOHN BELL Chief Financial Officer z SHELLEY JOURARD Director, Corporate Communications Patheon, Q3 200
Slide 2: Agenda and Forward-looking Information
Agenda z Update on strategic initiatives – Riccardo Trecroce, CEO z Financial results – John Bell, CFO z Operations report – Nick DiPietro, President and COO z Outlook – Riccardo Trecroce, CEO z Q&A Forward-looking Information This presentation contains forward-looking statements which reflect manag
Slide 3: Strategic Update: Update on Puerto Rico
STRATEGIC UPDATE Update on Puerto Rico z Working to eliminate losses as soon as possible z Actions during Q3 2007: − Reduced workforce by a further 230 positions to the end of August. Total reductions of ~450 positions (one-third of workforce) since start of fiscal year − Appointed new Site Director
Slide 4: Good progress on Canadian site restructuring
Good progress on Canadian site restructuring z Niagara/Burlington divestiture − Completed preliminary due diligence reviews − Next step: negotiate a definitive agreement with a preferred party z York Mills-Whitby consolidation − Have completed planning discussions with clients − Will begin product t
Slide 5: Q3 2007 Overview: Revenues and EBITDA
Q3 2007 Overview: Revenues z Revenues down $3.2M or 2% YOY z Europe up $16.5M or 26% (18% on a CER basis) − Client carve-out volumes in Italy and France − Strong PDS growth at Swindon, U.K. z North America down $19.8M or 17% − Almost 60% of decrease attributable to lower OTC volumes at Whitby and Ci
Slide 6: Q3 2007 Operating Results: Canada and U.S.
Q3 Operating Results: Canada z EBITDA before repositioning from Canadian commercial operations of $7.0M, up $0.9M − Significant decline in OTC volumes at Whitby, but operational improvements completely mitigated the impact of lower volumes on site profitability − Lower Rx volumes YOY at Toronto Regi
Slide 7: Q3 2007 Operating Results: Europe and Global PDS
Q3 2007 Operating Results: Europe z European commercial manufacturing EBITDA before repositioning costs of $14.7M, up $6.4M − Strong Large Volume Parenteral volumes in Italy − Significant earnings growth at Bourgoin-Jallieu, due to full commercial production of client carve-out volumes − Swindon pro
Slide 8: Write-down of Long-lived Assets and Repositioning Costs
Q3 2007 Results: Write-down of Long-lived Assets – Carolina, Puerto Rico z Recognized a non-cash impairment charge of $48.6M in Q3 2007 − $26.1M intangibles (value assigned to client contracts) − $22.5M tangibles z Based on forecast volume declines due to emergence of generic competition to Omnicef®
Slide 9: Interest, Tax Expense, Capital Expenditures and Earnings (Loss)
Q3 2007 Operating Results: Interest, Tax Expense, Capital Expenditures z Interest expense of $7.4M compared with $5.2M last year − Includes non-cash accretive interest charge of $3.5M for debt component of convertible preferred shares z Income tax charge of $5.3M compared with minor recovery last ye
Slide 10: Q3 YTD Highlights
Q3 YTD Highlights z Revenues of $510.3M versus $508.9M z EBITDA before repositioning costs of $69.1M (13.5% of revenues) versus $52.1M (10.2% of revenues) z Before the write down and repositioning costs, loss from continuing operations of $7.0M (7.5 cents per share) versus loss of $8.3M (9.0 cents p
Slide 11: Q3 Operational Highlights and Update on PDS
Q3 Operational Highlights z North America: − sustained performance improvements across all Canadian sites − Cincinnati continued transition towards higher-margin revenues − Significant improvements at Carolina, but challenges at Manati and Caguas z Europe: − J&J submitted NDA for ceftobiprole in May
Slide 12: Outlook: Update on Puerto Rico
Update on Puerto Rico z Launch of authorized generic offset declines in branded Omnicef at Carolina z Improved profitability at Carolina due to efficiency/productivity gains relative to last year z Manati results negatively impacted by lower-than-expected market demand for new product z Caguas resul
Slide 13: Outlook
Outlook z Expecting Q4 revenues to be lower than Q3 − Lower revenues in Europe due to normal summer shutdowns − Lower revenues in Puerto Rico due to declining volumes of Omnicef® Q3 2007 FINANCIAL RESULTS CONFERENCE CALL September 7, 2007 10:00 a.m. (EDT) Patheon, Q3 2007 webcast, Sept 7, 2007 13